AD patients were classified into two groups to further characterize clinical profiles based on the differential response to HDM: those producing IL-31 by CLA+ T cells were arranged into group 1 (n=17), and those with no IL-31 production were arranged into group 2 (n=41) (Figure 1A). This evidence concerns the gene IL31 and Alzheimer disease.